Austin Health

Title
A mixed blessing for liver transplantation patients - Rapamycin.
Publication Date
2023-02
Author(s)
Fan, Guang-Han
Zhang, Chen-Zhi
Gao, Feng-Qiang
Wei, Xu-Yong
Ling, Sun-Bin
Wang, Kai
Wang, Jian-Guo
Zheng, Shu-Sen
Nikfarjam, Mehrdad
Xu, Xiao
Subject
Hepatocellular carcinoma
Liver transplantation
Metabolic disease
Rapamycin
Tumor recurrence
Type of document
Journal Article
OrcId
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
DOI
10.1016/j.hbpd.2022.10.004
Abstract
Liver transplantation (LT) is an effective treatment option for end-stage liver disease. Mammalian target of rapamycin (mTOR) inhibitors, such as rapamycin, are widely used post LT.
Link
link
Citation
Hepatobiliary & Pancreatic Diseases International: HBPD INT 2023; 22(1)
Jornal Title
Hepatobiliary & Pancreatic Diseases International: HBPD INT

Files:

NameSizeformatDescriptionLink